Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M ...

It is joining the initial public offering (IPO) queue amid a flurry of IPO activity in the sector, with three biotechs ...

The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday ...

BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

The Medical News Today news team reports on emerging science, cutting-edge research, new treatments, and trending topics in health and medicine. All articles are written by our network of editors ...

The novel drugs work by mimicking the gut hormone GLP-1, which lowers blood sugar and limits the appetite. Treatments such as ...

Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings.